Major Shareholder BVF Commits to Support XOMA Royalty Merger with Ligand Pharmaceuticals
XOMA sits 83% above its 52-week low of $22.29 on elevated volume (3.2× avg).
Summary
Major shareholder Biotechnology Value Fund (BVF) has signed a voting agreement to support XOMA Royalty Corp's merger with Ligand Pharmaceuticals, committing to vote in favor and convert preferred shares.
Key Events · Ownership and Investor Activity · XOMA
-
Major Shareholder Commits to Merger
Biotechnology Value Fund (BVF), holding 21.4% of common stock and additional convertible preferred shares, entered a Voting and Support Agreement for the Ligand Pharmaceuticals merger.
-
Voting Agreement Details
BVF has agreed to vote all its shares in favor of the merger, convert its Series X Preferred Stock to common shares to enable voting, and irrevocably appointed Ligand as proxy.
-
Waiver of Appraisal Rights and No Sales
Under the agreement, BVF will not assert appraisal rights and has committed not to transfer, sell, pledge, or dispose of its shares during the term of the Support Agreement.
-
Preferred Stock Conversion
BVF will increase its Series X Beneficial Ownership Limitation to 45% and convert all its Series X Preferred Stock (5,003,000 shares) into common shares to vote on the merger.
Analysis · XOMA · Life Sciences
This Schedule 13D/A filing reveals that Biotechnology Value Fund (BVF), a significant shareholder holding 21.4% of XOMA Royalty Corp's common stock and convertible preferred shares, has entered into a Voting and Support Agreement with Ligand Pharmaceuticals. This agreement is crucial for the recently announced merger, where Ligand is set to acquire XOMA Royalty for $39.00 per share. BVF's commitment to vote its shares in favor of the merger, convert its Series X Preferred Stock to common shares to facilitate voting, waive appraisal rights, and refrain from selling shares, significantly increases the certainty of the merger's successful completion. This development provides strong institutional backing for the deal, despite the current market price of $40.70 trading above the offer price, suggesting the market may be anticipating a higher bid or is factoring in the time value of money until closing.
At the time of this filing, XOMA was trading at $40.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $488.4M. The 52-week trading range was $22.29 to $42.81. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.